intellia
therapeutics
names
john
crowley
board
directors
cambridge
globe
newswire
intellia
therapeutics
nasdaq
ntla
leading
genome
editing
company
focused
developing
curative
therapeutics
using
crispr
technology
vivo
ex
vivo
appointed
john
crowley
board
directors
crowley
leader
biotech
pharmaceuticals
visionary
advocate
advancement
treatments
people
living
rare
diseases
joins
intellia
board
pivotal
transition
company
expects
begin
first
clinical
trial
year
pleased
welcome
john
crowley
board
directors
widely
respected
work
companies
developed
transformational
treatments
rare
diseases
john
experiences
parent
advocate
children
pompe
disease
help
guide
intellia
pursue
mission
developing
curative
therapies
severe
diseases
said
intellia
president
chief
executive
officer
john
leonard
together
experienced
diverse
senior
leadership
team
intellia
board
directors
help
us
achieve
goals
deliver
value
patients
crowley
brings
relevant
experience
intellia
board
started
preeminent
biotech
companies
successful
programs
transitioned
preclinical
clinical
development
importantly
commercialized
medicine
available
patients
since
crowley
chairman
chief
executive
officer
amicus
therapeutics
global
biotechnology
company
focusing
developing
treatments
rare
genetic
diseases
amicus
managed
company
growth
small
one
operations
countries
market
value
billion
crowley
became
principal
advocate
treatment
severe
often
fatal
neuromuscular
disorder
pompe
disease
left
executive
position
large
pharmaceutical
company
novazyme
pharmaceuticals
born
desire
research
develop
treatment
two
children
diagnosed
pompe
crowley
oversaw
novazyme
acquisition
genzyme
corporation
sanofi
continued
senior
vice
president
played
lead
role
development
drugs
rare
diseases
held
governing
roles
several
nonprofits
including
global
genes
project
founding
board
member
foundation
america
former
national
chairman
crowley
also
member
university
council
science
technology
notre
dame
henry
crown
fellow
aspen
institute
crowley
family
recipient
family
exemplar
award
university
notre
dame
crowley
graduated
foreign
service
georgetown
university
earned
university
notre
dame
law
school
mba
harvard
business
school
outside
pioneering
work
biotech
crowley
served
commissioned
intelligence
officer
navy
reserve
decade
assigned
special
operations
command
combat
veteran
global
war
terrorism
service
afghanistan
additionally
perry
karsen
decided
step
board
position
effective
december
due
commitments
karsen
served
chairman
intellia
board
directors
april
february
including
company
initial
public
offering
remained
member
board
served
nominating
corporate
governance
committee
chaired
february
compensation
committee
past
five
years
perry
instrumental
helping
intellia
grow
privately
held
biotech
publicly
traded
company
today
added
leonard
grateful
stewardship
direction
friendship
brought
board
employees
wish
best
future
endeavors
applies
leadership
endeavors
west
intellia
therapeutics
intellia
therapeutics
leading
genome
editing
company
focused
development
proprietary
potentially
curative
therapeutics
using
crispr
system
intellia
believes
crispr
technology
potential
transform
medicine
producing
therapeutics
permanently
edit
correct
genes
creating
enhanced
engineered
cells
treat
oncological
immunological
diseases
intellia
combination
deep
scientific
technical
clinical
development
experience
along
leading
intellectual
property
portfolio
puts
unique
position
unlock
broad
therapeutic
applications
crispr
technology
create
new
classes
therapeutic
products
learn
intellia
therapeutics
crispr
follow
us
twitter
intelliatweets
statements
press
release
contains
statements
intellia
therapeutics
intellia
within
meaning
private
securities
litigation
reform
act
statements
include
limited
express
implied
statements
regarding
intellia
ability
advance
expand
crispr
technology
develop
human
therapeutic
products
well
crispr
intellectual
property
portfolio
achieve
stable
effective
genome
editing
timing
potential
achievement
milestones
advance
pipeline
grow
company
anticipated
contribution
members
board
directors
executives
operations
progress
statements
press
release
based
management
current
expectations
beliefs
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
risks
related
intellia
ability
protect
maintain
intellectual
property
position
risks
related
intellia
relationship
third
parties
including
licensors
licensees
risks
related
ability
licensors
protect
maintain
intellectual
property
position
uncertainties
related
authorization
initiation
conduct
studies
development
requirements
product
candidates
risk
one
intellia
product
candidates
successfully
developed
commercialized
risk
results
preclinical
studies
clinical
studies
predictive
future
results
connection
future
studies
risk
intellia
collaborations
novartis
regeneron
ex
vivo
collaborations
continue
successful
discussion
risks
uncertainties
important
factors
could
cause
intellia
actual
results
differ
contained
statements
see
section
entitled
risk
factors
intellia
recent
annual
report
form
well
discussions
potential
risks
uncertainties
important
factors
intellia
filings
securities
exchange
commission
information
press
release
date
release
intellia
undertakes
duty
update
information
unless
required
law
intellia
contacts
media
jennifer
mound
smoter
senior
vice
president
external
affairs
communications
lynnea
olivarez
director
external
affairs
communications
investors
lina
li
associate
director
investor
relations
